Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo varenicline Clear all
Recruiting Phase 2 Interventional

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

NCT06679374
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Varenicline
Drug
Lead sponsor
Vikas Kotagal
Other
Eligibility
45 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Alternative Dosing Schedule of Varenicline for Smoking Cessation

NCT00835900
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline, placebo
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Chantix for Treating Cocaine Dependence

NCT00567008
View directory record Official record
Conditions
Cocaine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Study In Healthy Adolescent Smokers

NCT01312909
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 19 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
56
States / cities
Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UW Quitting Using Intensive Treatment Study (QUITS)

NCT03176784
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Nicotine patch, Placebo Patch, Placebo Pill
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

NCT00992771
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
varenicline, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 8, 2026, 2:17 AM EDT
Terminated Phase 4 Interventional Results available

Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents

NCT04602494
View directory record Official record
Conditions
Vaping, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 8, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cannabis-Tobacco Co-Use Treatment Study

NCT06883162
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Interventions
Varenicline, Counseling, Psychosocial modules
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Varenicline for Alcohol Dependence

NCT01146613
View directory record Official record
Conditions
Alcoholism
Interventions
Varenicline, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • Bedford, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 8, 2026, 2:17 AM EDT
Terminated Phase 2Phase 3 Interventional

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

NCT00803868
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
varenicline, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline for the Treatment of Smokeless Tobacco

NCT00813917
View directory record Official record
Conditions
Nicotine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT04036292
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Treatment for Methadone Maintenance Patients

NCT01027754
View directory record Official record
Conditions
Smoking Cessation, Substance-Related Disorders
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence

NCT03538808
View directory record Official record
Conditions
Medication Adherence
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline OTC Trial on Efficacy and Safety

NCT03557294
View directory record Official record
Conditions
Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
Interventions
1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d., 0.0mg placebo Varenicline b.i.d.
Drug
Lead sponsor
Arizona State University
Other
Eligibility
21 Years and older
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Burbank, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

NCT00150241
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

NCT00773422
View directory record Official record
Conditions
Smoking
Interventions
naltrexone, varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Advancing Tobacco Use Treatment for African American Smokers

NCT02360631
View directory record Official record
Conditions
Smoking Cessation
Interventions
Chantix, Placebo
Drug
Lead sponsor
Lisa Sanderson Cox, PhD
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

NCT00580853
View directory record Official record
Conditions
Smoking Lapse Behavior
Interventions
varenicline, bupropion, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 8, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 8, 2026, 2:17 AM EDT